Answers are grounded in this paper and cite their sources.
INTRODUCTION: Crohn's disease (CD) remains a major clinical challenge, since many patients fail biologics or lose response. Selective IL-23p19 blockade is mechanistically attractive, targeting the IL-23/Th17 axis while preserving IL-12-dependent host defense. Risankizumab, the first selective IL-23p19 inhibitor approved for CD, is increasingly used in advanced therapy-experienced patients. AREAS COVERED: This narrative review summarizes risankizumab pharmacology, pivotal trial data, real-world effectiveness and safety in moderate-to-severe CD, emphasizing biologic-experienced and multiply exposed populations, based on PubMed, Scopus and Google Scholar searches (from inception to October 2026). It also examines difficult-to-treat phenotypes (postoperative recurrence, CD of the pouch, perianal, fistulising and stricturing disease, extraintestinal manifestations) and compares risankizumab with other IL-23p19 inhibitors. Positioning is discussed in light of the SEQUENCE trial and 2025 ACG and AGA guidelines, together with unresolved issues: special populations, predictive biomarkers and investigational combination therapy. EXPERT OPINION: Risankizumab is not a universal solution for refractory CD, but it is one of the best-supported options after anti-TNF failure, particularly for endoscopic outcomes. Evidence in multiply exposed patients and difficult-to-treat phenotypes is largely observational, and superiority over anti-TNF agents as first-line therapy is unproven. Major gaps persist in fistulising disease, special populations, head-to-head comparisons, predictive biomarkers, and sequencing or combination strategies.
No takes yet. Share an insight, caveat, or question.
Vincenzo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: